KHRN.V - Khiron Life Sciences Corp.

TSXV - TSXV Delayed Price. Currency in CAD
1.8800
-0.0600 (-3.09%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close1.9400
Open1.9200
Bid1.8800 x 0
Ask1.8900 x 0
Day's Range1.8400 - 1.9300
52 Week Range0.8800 - 4.3500
Volume340,793
Avg. Volume485,634
Market Cap204.471M
Beta (3Y Monthly)4.09
PE Ratio (TTM)N/A
EPS (TTM)-0.4360
Earnings DateMay 30, 2019 - May 30, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.58
  • How Khiron Life Sciences Corp. (CVE:KHRN) Could Add Value To Your Portfolio
    Simply Wall St.

    How Khiron Life Sciences Corp. (CVE:KHRN) Could Add Value To Your Portfolio

    I've been keeping an eye on Khiron Life Sciences Corp. (CVE:KHRN) because I'm attracted to its fundamentals. Looking...

  • CNW Group

    Khiron Announces DTC Eligibility, Increasing Access for U.S. Investors

    TORONTO , Aug. 20, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (KHRNF), (Frankfurt:A2JMZC), an integrated cannabis company with core operations in Latin America, announced today that its shares have received Depository Trust Company (DTC) full-service eligibility in the United States . DTC eligibility is expected to simplify the process of trading and transferring of the Company's common shares in the United States .

  • PR Newswire

    Khiron Provides Clarification of August 12, 2019 News Release

    TORONTO, Aug. 14, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt: A2JMZC), an integrated cannabis company with core operations in Latin America, wishes to clarify specific disclosure relating to the news release disseminated by the Company on August 12, 2019. Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis.

  • PR Newswire

    Khiron Boosts European Expansion With Key Executive Appointments

    Experienced capital markets leader and cannabis industry executive Tejinder Virk is appointed President of Khiron Europe Accomplished cannabis legal expert Franziska Katterbach joins Company as Chief Legal ...

  • CNW Group

    Khiron Launches Revenue-Generating Pilot Program With Top Colombian Health Insurance Provider

    Khiron Launches Revenue-Generating Pilot Program With Top Colombian Health Insurance Provider

  • CNW Group

    Khiron Signs Kuida Distribution Agreement with Grupo Éxito, South America's Market Leading Retail Group

    Grupo Éxito has a multinational retail presence in Colombia , Brazil , Argentina and Uruguay and operates 1,533 stores. Kuida to be introduced as key addition to the retailer's cosmetics products category, with experience centres and consultants in each Éxito WOW store to support sales and brand awareness.

  • Benzinga

    Joint Venture Between Khiron Life Sciences, Dixie Brands Receives TSX Conditional Approval

    The previously announced 50/50 joint venture between Khiron Life Sciences Corp. (TSXV: KHRN) and Dixie Brands Inc. (CSE: DIXI.U) has received its conditional approval from the TSX Venture Exchange. The conditional approval will kickstart two endeavors: In the U.S., the distribution and sales of its Kuida cosmeceutical line will soon begin, while Latin America will be introduced to Dixie's CBD-infused line. The joint venture also plans to create new products aimed at the Latin American market.

  • Khiron and Dixie Receive Conditional TSXV Approval for Roll-Out of Kuida Cosmeceutical Line in U.S. Market and Cannabis-Infused Products in Latin America
    CNW Group

    Khiron and Dixie Receive Conditional TSXV Approval for Roll-Out of Kuida Cosmeceutical Line in U.S. Market and Cannabis-Infused Products in Latin America

    Khiron and Dixie Receive Conditional TSXV Approval for Roll-Out of Kuida Cosmeceutical Line in U.S. Market and Cannabis-Infused Products in Latin America

  • CNW Group

    Khiron Provides Update on Canapalife Group Transaction

    TORONTO , Aug. 1, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt:A2JMZC), an integrated cannabis company with core operations in Latin America, today provided an update on the Company's previously announced non-binding LOI with Canapalife Group. The Company confirms the expiry of the LOI and that the parties have mutually agreed not to proceed with the proposed transaction. Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America.

  • PR Newswire

    Khiron Begins Pre-clinical Medical Cannabis Studies with Leading Academic Institutes in Uruguay

    Patient-focused studies advance progress towards global clinical trials on Khiron strains to treat inflammation, oxidative and nervous system disorders Co-sponsored with Uruguay government using Company ...

  • CNW Group

    Khiron Announces Final Approval of Acquisition of NettaGrowth

    Khiron Announces Final Approval of Acquisition of NettaGrowth

  • PR Newswire

    Khiron Life Sciences Added to NYSE-Listed The Cannabis ETF

    TORONTO, July 25, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (KHRNF), (Frankfurt: A2JMZC), an integrated cannabis company with core operations in Latin America, announced today that it has been added to The Cannabis ETF (NYSE:THCX) ("THCX"), which trades on the New York Stock Exchange. Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America.

  • Market Exclusive

    Khiron Gets Approval to Commercialize 17 Cannabis Strains in Colombia

    Khiron Life Sciences (TSXV: KHRN) (OTCQB: KHRNF) (Frankfurt: A2JMZC) has received approval from the National Cultivar Registry and the Technical Direction of the ICA for the commercialization of 17 stains of cannabis. The approvals bring the total number of registered strains to 22 and positions Khiron to commercialize and distribute CBD cannabis, which is currently […]The post Khiron Gets Approval to Commercialize 17 Cannabis Strains in Colombia appeared first on Market Exclusive.

  • Market Exclusive

    Cannabis Stock News Daily Roundup July 18

    CannabCo Pharmaceutical Corp. Colombia S.A.S., a Colombia based cannabis cultivator and manufacturer of medical cannabis products, has completed a deal with Invest In Orinoquia for the development of thousands of hectares of cannabis and hemp production in the Los Llanos region of Colombia. The joint venture will proceed with the deployment of "purpose-built" cannabis greenhouses […]The post Cannabis Stock News Daily Roundup July 18 appeared first on Market Exclusive.